Market Research Report
Melanoma - Pipeline Review, H2 2018
|Published by||Global Markets Direct||Product code||232839|
|Published||Content info||2285 Pages
Delivery time: 1-2 business days
|Melanoma - Pipeline Review, H2 2018|
|Published: December 21, 2018||Content info: 2285 Pages||
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Melanoma - Pipeline Review, H2 2018, provides an overview of the Melanoma (Oncology) pipeline landscape.
Melanoma is a tumor that develops as a result of the malignant transformation of melanocytes. These cells are derived from the neural crest. Melanomas usually occur on the skin but can arise in other locations where neural crest cells migrate, such as in the gastrointestinal tract or brain. It is more common in women than in men. In women, the most common site is the legs and melanomas in men are most common on the back. Unusual moles, sores, lumps, blemishes, markings, or changes in the way an area of the skin looks or feels are sign of melanoma. Treatment includes surgery, radiation and proton therapy.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Melanoma - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 18, 126, 141, 1, 11, 223, 33 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 18, 16, 75 and 11 molecules, respectively.
Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.